2015
DOI: 10.1371/journal.pone.0130271
|View full text |Cite
|
Sign up to set email alerts
|

Heparin and Protamine Titration Does Not Improve Haemostasis after Cardiac Surgery: A Prospective Randomized Study

Abstract: BackgroundBleeding complications are common in cardiac surgery. Perioperative handling of heparin and protamine may influence the haemostasis. We hypothesized that heparin and protamine dosing based on individual titration curves would improve haemostasis in comparison to standard dosing.Subjects and MethodsSixty patients scheduled for first time elective coronary artery bypass grafting or valve surgery were included in a prospective randomized study. The patients were randomized to heparin and protamine dosin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
9
0
1

Year Published

2016
2016
2023
2023

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 24 publications
(11 citation statements)
references
References 30 publications
1
9
0
1
Order By: Relevance
“…167 A Hepconbased anticoagulation strategy did not influence heparin and protamine dosing or postoperative haemostasis or bleeding compared to ACT-based dosing. 168 Contrarily, the use of the Hepcon/HMS device resulted in a highly significant difference for the total protamine dose compared to ACT-based dosing (mean protamine dose: 14.190 IU vs 24.777 IU; P < 0.001) and total blood volume (mean blood loss: 804 ml vs 1416 ml; P < 0.001), whereas there was no difference in the total heparin dose. 169 Due to the lack of perioperative bleeding and transfusion rates as primary end points in these studies, larger multicentre studies are required to determine the added value of individual heparin management in the modern cardiosurgical setting.…”
Section: Interventionsmentioning
confidence: 96%
“…167 A Hepconbased anticoagulation strategy did not influence heparin and protamine dosing or postoperative haemostasis or bleeding compared to ACT-based dosing. 168 Contrarily, the use of the Hepcon/HMS device resulted in a highly significant difference for the total protamine dose compared to ACT-based dosing (mean protamine dose: 14.190 IU vs 24.777 IU; P < 0.001) and total blood volume (mean blood loss: 804 ml vs 1416 ml; P < 0.001), whereas there was no difference in the total heparin dose. 169 Due to the lack of perioperative bleeding and transfusion rates as primary end points in these studies, larger multicentre studies are required to determine the added value of individual heparin management in the modern cardiosurgical setting.…”
Section: Interventionsmentioning
confidence: 96%
“…53 Heparin management systems may reduce the total dose of protamine, blood loss, and transfusion, although study results have been mixed. [53][54][55][56][57] Heparin resistance occurs when a patient requires much higher than anticipated dosing to achieve an acceptable ACT pre-CPB, and can be defined as an inability to achieve a therapeutic ACT with > 600 IU/kg of heparin. 58 Heparin resistance may be due to high plasma fibrinogen, thrombocytosis, or congenital or acquired antithrombin deficiency.…”
Section: Heparin Management and Protamine Reversalmentioning
confidence: 99%
“…150,151,153,[158][159][160] In contrast, others did not show favourable results for blood loss and transfusion requirements when heparin titration was compared with an ACT-based protocol. 152,[161][162][163] Due to the lack of perioperative bleeding and transfusion rates as primary end points in these studies, larger multicentre RCTs are required to determine the added value of individual heparin management. Alternative methods of heparin management and anticoagulation monitoring during ECC consist of the determination of anti-factor Xa activity.…”
Section: Description Of the Evidencementioning
confidence: 99%